c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: A mechanism by which cancer cells acquire cisplatin resistance

Science Signaling

Volumn 4, Issue 166, 2011, Pages

  Pyndiah, Slovénie ^a,d   Tanida, Satoshi ^a,e   Ahmed, Kazi M ^b,c,f   Cassimere, Erica K ^a,b,c,g   Choe, Chungyoul ^a   Sakamuro, Daitoku ^a,b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Purdue University   (United States)

^c PURDUE UNIVERSITY   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIDGING INTEGRATOR 1 PROTEIN; CISPLATIN; MYC INTERACTING ZINC FINGER TRANSCRIPTION FACTOR 1; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEIC ACID BINDING PROTEIN; PROTEIN P53; STAUROSPORINE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIN1 PROTEIN, HUMAN; BIN1 PROTEIN, MOUSE; MIZ1 PROTEIN, MOUSE; MYC PROTEIN, HUMAN; NERVE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; PARP1 PROTEIN, MOUSE; PIAS2 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER RESISTANCE; CATALYSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA REPAIR; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; ONCOGENE C MYC; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TRANSACTIVATION; ANIMAL; CELL DIVISION; DNA DAMAGE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 79953251340     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001556     Document Type: Article

References (66)

1. B. Rosenberg, L. VanCamp, J. E. Trosko, V. H. Mansour, Platinum compounds: A new class of potent antitumour agents. Nature 222, 385-386 (1969).
2. L. Kelland, The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007).
3. V. Brabec, J. Kasparkova, Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat. 8, 131-146 (2005).
4. Z. H. Siddik, Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
5. L. P. Martin, T. C. Hamilton, R. J. Schilder, Platinum resistance: The role of DNA repair pathways. Clin. Cancer Res. 14, 1291-1295 (2008).
6. J. E. Visvader, G. J. Lindeman, Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
7. J. M. Rosen, C. T. Jordan, The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673 (2009).
8. V. H. Cowling, M. D. Cole, Mechanism of transcriptional activation by the Myc oncoproteins. Semin. Cancer Biol. 16, 242-252 (2006).
9. M. Eilers, R. N. Eisenman, Myc's broad reach. Genes Dev. 22, 2755-2766 (2008).
10. M. Wanzel, S. Herold, M. Eilers, Transcriptional repression by Myc. Trends Cell Biol. 13, 146-150 (2003).
11. S. Pelengaris, M. Khan, G. Evan, c-MYC: More than just a matter of life and death. Nat. Rev. Cancer 2, 764-776 (2002).
12. D. Sakamuro, G. C. Prendergast, New Myc-interacting proteins: A second Myc network emerges. Oncogene 18, 2942-2954 (1999).
13. C. V. Dang, K. A. O'Donnell, K. I. Zeller, T. Nguyen, R. C. Osthus, F. Li, The c-Myc target gene network. Semin. Cancer Biol. 16, 253-264 (2006).
14. N. Meyer, L. Z. Penn, Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990 (2008).
15. M. D. Sklar, E. V. Prochownik, Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res. 51, 2118-2123 (1991).
16. Y. Mizutani, M. Fukumoto, B. Bonavida, O. Yoshida, Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 74, 2546-2554 (1994).
17. C. Leonetti, A. Biroccio, A. Candiloro, G. Citro, C. Fornari, M. Mottolese, D. Del Bufalo, G. Zupi, Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin. Cancer Res. 5, 2588-2595 (1999).
18. D. Sakamuro, V. Eviner, K. J. Elliott, L. Showe, E. White, G. C. Prendergast, c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 11, 2411-2418 (1995).
19. D. Sakamuro, K. J. Elliott, R. Wechsler-Reya, G. C. Prendergast, BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat. Genet. 14, 69-77 (1996).
20. K. Elliott, D. Sakamuro, A. Basu, W. Du, W. Wunner, P. Staller, S. Gaubatz, H. Zhang, E. Prochownik, M. Eilers, G. C. Prendergast, Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 18, 3564-3573 (1999).
21. K. Elliott, K. Ge, W. Du, G. C. Prendergast, The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene 19, 4669-4684 (2000).
22. J. B. DuHadaway, D. Sakamuro, D. L. Ewert, G. C. Prendergast, Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res. 61, 3151-3156 (2001).
23. E. K. Cassimere, S. Pyndiah, D. Sakamuro, The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ. 16, 1641-1653 (2009).
24. K. Ge, J. Duhadaway, D. Sakamuro, R. Wechsler-Reya, C. Reynolds, G. C. Prendergast, Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int. J. Cancer 85, 376-383 (2000).
25. K. Ge, F. Minhas, J. Duhadaway, N. C. Mao, D. Wilson, R. Buccafusca, D. Sakamuro, P. Nelson, S. B. Malkowicz, J. Tomaszewski, G. C. Prendergast, Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int. J. Cancer 86, 155-161 (2000).
26. A. Ghaneie, V. Zemba-Palko, H. Itoh, K. Itoh, D. Sakamuro, S. Nakamura, A. P. Soler, G. C. Prendergast, Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol. Ther. 6, 192-194 (2007).
27. R. Radpour, C. Kohler, M. M. Haghighi, A. X. Fan, W. Holzgreve, X. Y. Zhong, Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 28, 2969-2978 (2009).
28. M. Y. Chang, J. Boulden, E. Sutanto-Ward, J. B. Duhadaway, A. P. Soler, A. J. Muller, G. C. Prendergast, Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res. 67, 100-107 (2007).
29. M. Y. Chang, J. Boulden, J. B. Katz, L. Wang, T. J. Meyer, A. P. Soler, A. J. Muller, G. C. Prendergast, Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 67, 7605-7612 (2007).
30. J. M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F. J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon, G. de Murcia, Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U.S.A. 94, 7303-7307 (1997).
31. V. Schreiber, F. Dantzer, J. C. Ame, G. de Murcia, Poly(ADP-ribose): Novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528 (2006).
32. E. L. Kinney, S. Tanida, A. A. Rodrigue, J. K. Johnson, V. S. Tompkins, D. Sakamuro, Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1- dependentmechanism. J. Cell. Physiol. 216, 621-631 (2008).
33. X. Yin, C. Giap, J. S. Lazo, E. V. Prochownik, Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22, 6151-6159 (2003).
34. A. V. Follis, D. I. Hammoudeh, H. Wang, E. V. Prochownik, S. J. Metallo, Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 15, 1149-1155 (2008).
35. M. L. Meyer-Ficca, R. G. Meyer, E. L. Jacobson, M. K. Jacobson, Poly(ADP-ribose) polymerases: Managing genome stability. Int. J. Biochem. Cell Biol. 37, 920-926 (2005).
36. + into a nuclear signal. Genes Dev. 19, 1951-1967 (2005).
37. S. F. El-Khamisy, M. Masutani, H. Suzuki, K. W. Caldecott, A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 31, 5526-5533 (2003).
38. M. Masson, C. Niedergang, V. Schreiber, S. Muller, J. Menissier-de Murcia, G. de Murcia, XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. 18, 3563-3571 (1998).
39. H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N. J. Curtin, T. Helleday, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
40. H. Farmer, N. McCabe, C. J. Lord, A. N. Tutt, D. A. Johnson, T. B. Richardson, M. Santarosa, K. J. Dillon, I. Hickson, C. Knights, N. M. Martin, S. P. Jackson, G. C. Smith, A. Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
41. C. Rauh-Adelmann, K. M. Lau, N. Sabeti, J. P. Long, S. C. Mok, S. M. Ho, Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol. Carcinog. 28, 236-246 (2000).
42. H. Lee, A. H. Trainer, L. S. Friedman, F. C. Thistlethwaite, M. J. Evans, B. A. Ponder, A. R. Venkitaraman, Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol. Cell 4, 1-10 (1999).
43. J. H. Sheen, J. K. Woo, R. B. Dickson, c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells. Br. J. Cancer 89, 1479-1485 (2003).
44. S. Kagaya, C. Kitanaka, K. Noguchi, T. Mochizuki, A. Sugiyama, A. Asai, N. Yasuhara, Y. Eguchi, Y. Tsujimoto, Y. Kuchino, A functional role for death proteases in s-Myc- and c-Myc-mediated apoptosis. Mol. Cell. Biol. 17, 6736-6745 (1997).
45. L. Desbarats, S. Gaubatz, M. Eilers, Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev. 10, 447-460 (1996).
46. R.Wechsler-Reya, D. Sakamuro, J. Zhang, J. Duhadaway, G. C. Prendergast, Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J. Biol. Chem. 272, 31453-31458 (1997).
47. R. Javahery, A. Khachi, K. Lo, B. Zenzie-Gregory, S. T. Smale, DNA sequence requirements for transcriptional initiator activity in mammalian cells. Mol. Cell. Biol. 14, 116-127 (1994).
48. K. Peukert, P. Staller, A. Schneider, G. Carmichael, F. Hänel, M. Eilers, An alternative pathway for gene regulation by Myc. EMBO J. 16, 5672-5686 (1997).
49. INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3, 392-399 (2001).
50. S. Wu, C. Cetinkaya, M. J. Munoz-Alonso, N. von der Lehr, F. Bahram, V. Beuger, M. Eilers, J. Leon, L. G. Larsson, Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 22, 351-360 (2003).
51. R. J. Wechsler-Reya, K. J. Elliott, G. C. Prendergast, A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol. Cell. Biol. 18, 566-575 (1998).
52. E. V. Prochownik, c-Myc: Linking transformation and genomic instability. Curr. Mol. Med. 8, 446-458 (2008).
53. W. C. Gustafson, W. A. Weiss, Myc proteins as therapeutic targets. Oncogene 29, 1249-1259 (2010).
54. K. Fujimoto, M. Takahashi, Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA. Biochem. Biophys. Res. Commun. 241, 775-781 (1997).
55. J. Wang, L. Y. Xie, S. Allan, D. Beach, G. J. Hannon, Myc activates telomerase. Genes Dev. 12, 1769-1774 (1998).
56. Y. Kondo, S. Kondo, Y. Tanaka, T. Haqqi, B. P. Barna, J. K. Cowell, Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16, 2243-2248 (1998).
57. P. Phatak, A. M. Burger, Telomerase and its potential for therapeutic intervention. Br. J. Pharmacol. 152, 1003-1011 (2007).
58. F. d'Adda di Fagagna, M. P. Hande, W. M. Tong, P. M. Lansdorp, Z. Q. Wang, S. P. Jackson, Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat. Genet. 23, 76-80 (1999).
59. A. Ramalingam, G. E. Farmer, T. D. Stamato, G. C. Prendergast, Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle 6, 1914-1918 (2007).
60. G. Grelle, S. Kostka, A. Otto, B. Kersten, K. F. Genser, E. C. Müller, S. Wälter, A. Böddrich, U. Stelzl, C. Hänig, R. Volkmer-Engert, C. Landgraf, S. Alberti, J. Höhfeld, M. Strödicke, E. E. Wanker, Identification of VCP/p97, carboxyl terminus of Hsp70-interacting protein (CHIP), and amphiphysin II interaction partners using membrane-based human proteome arrays. Mol. Cell. Proteomics 5, 234-244 (2006).
61. M. R. Lieber, The mechanism of double-strand DNA break repair by the non-homologous DNA end-joining pathway. Annu. Rev. Biochem. 79, 181-211 (2010).
62. G. C. Prendergast, Immune escape as a fundamental trait of cancer: Focus on IDO. Oncogene 27, 3889-3900 (2008).
63. A. J. Muller, J. B. DuHadaway, P. S. Donover, E. Sutanto-Ward, G. C. Prendergast, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.Nat.Med. 11, 312-319 (2005).
64. A. Rongvaux, F. Andris, F. Van Gool, O. Leo, Reconstructing eukaryotic NAD metabolism. Bioessays 25, 683-690 (2003).
65. M. Rouleau, A. Patel, M. J. Hendzel, S. H. Kaufmann, G. G. Poirier, PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293-301 (2010).
66. Acknowledgments: We thank W. Vedeckis, A. Ochoa, J. Strong, S. Parthasarathy, S. M. Jazwinski, and V. Jo Davisson for helpful discussions; K. Speicher and G. Jarori for technical support with mass spectrometry; and G. C. Prendergast for critical reading of the manuscript. Funding: This work was supported by the Louisiana Cancer Research Consortium Funds, the U.S. Army Department of Defense Prostate Cancer Research Program (DAMD 17-02-1-0131), the Walther Cancer Foundation, the Wendy Will Case Cancer Fund, and the Susan G. Komen Foundation (to D.S.), and by a U.S. NIH-sponsored predoctoral fellowship (1F31CA110205-01) (to E.K.C.). Author contributions: S.P., S.T., K.M.A., E.K.C., C.C., and D.S. designed and performed the experiments and analyzed the data; D.S. supervised the project and wrote the manuscript. Competing interests: D.S. holds a 1999 U.S. Patent with G. C. Prendergast, no. 6,410,238, "Box-dependent Myc-interacting protein (Bin1) compositions and uses thereof" (The Wistar Institute of Anatomy and Biology, Philadelphia, PA).